1403767-19-0 Usage
General Description
6-Bromo-5-hydroxy-1-methyl-1H-indazole is a chemical compound with the molecular formula C8H7BrN2O. It belongs to the class of indazoles which are heterocyclic aromatic organic compounds. This specific compound is a derivative of indazole, which is a bicyclic compound that consists of a pyrazole ring fused to a benzene ring. It is characterized by the presence of a bromine atom, a hydroxyl group, and a methyl group attached to the indazole ring. 6-BroMo-5-hydroxy-1-Methyl-1H-indazole may have potential applications in pharmaceutical research and drug development due to its unique structure and potential biological activities, although further studies would be needed to determine its specific properties and potential uses.
Check Digit Verification of cas no
The CAS Registry Mumber 1403767-19-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,0,3,7,6 and 7 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1403767-19:
(9*1)+(8*4)+(7*0)+(6*3)+(5*7)+(4*6)+(3*7)+(2*1)+(1*9)=150
150 % 10 = 0
So 1403767-19-0 is a valid CAS Registry Number.
1403767-19-0Relevant articles and documents
TRICYCLIC FURAN-SUBSTITUTED PIPERIDINEDIONE COMPOUND
-
, (2021/07/17)
Disclosed are a series of tricyclic furan-substituted piperidinedione compounds and an application thereof in preparing a drug for treating a disease related to CRBN protein. In particular, disclosed is a derivative compound represented by formula (I) or a pharmaceutically acceptable salt thereof.
Route design and development of a MET kinase inhibitor: A copper-catalyzed preparation of an N 1 - Methylindazole
Kallman, Neil J.,Liu, Chin,Yates, Matthew H.,Linder, Ryan J.,Ruble, J. Craig,Kogut, Eugene F.,Patterson, Lawrence E.,Laird, Dana L. T.,Hansen, Marvin M.
, p. 501 - 510 (2014/05/06)
The synthesis of a MET kinase inhibitor in an overall yield of 22% was achieved over eight steps starting with 3-hydroxybenzaldehyde, an improvement from the initial 12-step process with a 5.4% yield. Highlights of the process chemistry design and development are a Cu-catalyzed cyclization to form an important N1-methylindazole ring, a selective nitro reduction in the presence of an aryl bromide, a late-stage Suzuki cross-coupling, and a base-promoted Boc deprotection to form the desired drug candidate.
